Retrophin to conduct initial public offering of stock with greenshoe

Deal funds clinical trials and development, general corporate purposes

By Devika Patel

Knoxville, Tenn., Dec. 18 - Retrophin, Inc. will price an initial public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Proceeds will be used for clinical trials and development, general corporate purposes and working capital.

The biopharmaceutical company is based in New York. It expects its shares will trade on the Nasdaq under the symbol "RTRX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.